NeurAxon Closes a Convertible Debt Financing Deal

NeurAxon Inc. closed a convertible debt financing. The Canadian developer of next-generation pain therapeutics said the debt can be exchanged for class B preferred shares for a total of about $14 million. CTI Life Sciences Fund, the Ontario Capital Growth Corp., Delphi Ventures, OrbiMed Advisor, LLC, Ventures West Capital Ltd., H.I.G. Ventures, BDC Venture Capital, NeuroVentures Fund and NeurAxon CEO Lawrence Bloch were investors.

North AmericaUSBriefs